{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:20:30Z","timestamp":1791231630710,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.gore.2021.100878","type":"journal-article","created":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T13:02:44Z","timestamp":1633784564000},"page":"100878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review"],"prefix":"10.1016","volume":"38","author":[{"given":"Jawaher","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yussra","family":"Eltigani Mohmmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Ghazal-Aswad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidayath","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed M.J.","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Hassoun Hadid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Rizwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raya","family":"Almazrouei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Dawoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathi","family":"Azribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Elhasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rahman","family":"Al Sumaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Al-Qawasmeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Glaholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Balaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2021.100878_b0005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ijc.32078","article-title":"Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina","volume":"145","author":"Bertoli","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.gore.2021.100878_b0010","doi-asserted-by":"crossref","unstructured":"Brahmer, J.R., et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-68. https:\/\/doi.org\/10.1200\/jco.2017.77.6385.","DOI":"10.1200\/JCO.2017.77.6385"},{"issue":"17","key":"10.1016\/j.gore.2021.100878_b0015","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.gore.2021.100878_b0020","doi-asserted-by":"crossref","unstructured":"Creasman, W.T., Phillips, J.L., Menck, H.R. The National Cancer Data Base report on cancer of the vagina. Cancer 83(5):1033\u2013 1040). doi: 10.1002\/(SICI)1097-0142(19980901)83:5<1033::AID-CNCR30>3.0.CO;2-6.","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<1033::AID-CNCR30>3.0.CO;2-6"},{"issue":"2","key":"10.1016\/j.gore.2021.100878_b0025","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1006\/gyno.2001.6502","article-title":"A population-based study of squamous cell vaginal cancer: HPV and cofactors","volume":"84","author":"Daling","year":"2002","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.gore.2021.100878_b0030","doi-asserted-by":"crossref","unstructured":"Dalrymple, J.L., et al. Chemoradiation for primary invasive squamous carcinoma of the vagina. Int J Gynecol Cancer. 2004 Jan-Feb; 14(1):110-7. https:\/\/doi.org\/10.1111\/j.1048-891x.2004.014066.x.","DOI":"10.1136\/ijgc-00009577-200401000-00015"},{"issue":"11","key":"10.1016\/j.gore.2021.100878_b0035","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.gore.2021.100878_b0040","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.gore.2021.100878_b0045","doi-asserted-by":"crossref","unstructured":"Gadducci, A., Guerrieri, M.E. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. Anticancer Research, 37 (11) 5955-5965. https:\/\/doi.org\/10.21873\/anticanres.12042.","DOI":"10.21873\/anticanres.12042"},{"key":"10.1016\/j.gore.2021.100878_b0050","unstructured":"https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf (accessed 9th Sept 2021)."},{"key":"10.1016\/j.gore.2021.100878_b0055","unstructured":"https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/22-Vagina-fact-sheet.pdf (accessed 11th Sept 2021)."},{"key":"10.1016\/j.gore.2021.100878_b0060","unstructured":"Keytruda (pembrolizumab) injection for intravenous prescribing information, Merck and Co, Inc. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125514s084lbl.pdf. Accessed Nov 30th 2020."},{"key":"10.1016\/j.gore.2021.100878_b0065","doi-asserted-by":"crossref","unstructured":"Klein O, et al. Combination immunotherapy with ipilumumab and nivolumab in patients with rare gynaecological malignancies. Journal of Clinical Oncology 2020 38:15_suppl, 6091-6091. https:\/\/www.doi.org\/10.1200\/jco.2020.38.15_suppl.6091.","DOI":"10.1200\/JCO.2020.38.15_suppl.6091"},{"issue":"3","key":"10.1016\/j.gore.2021.100878_b0070","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijrobp.2004.12.011","article-title":"FDG-PET evaluation of vaginal carcinoma","volume":"62","author":"Lamoreaux","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"11","key":"10.1016\/j.gore.2021.100878_b0075","first-page":"1166","article-title":"ACR appropriateness criteria management of vaginal cancer","volume":"27","author":"Lee","year":"2013","journal-title":"Oncology (Williston Park)."},{"issue":"30","key":"10.1016\/j.gore.2021.100878_b0080","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.gore.2021.100878_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065048","article-title":"Concurrent chemoradiation for vaginal cancer","volume":"8","author":"Miyamoto","year":"2013","journal-title":"PLoS One."},{"issue":"4","key":"10.1016\/j.gore.2021.100878_b0090","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0360-3016(03)00217-7","article-title":"High-dose-rate (HDR) brachytherapy with or without external beam radiotherapy in the treatment of primary vaginal carcinoma: long-term results and side effects","volume":"56","author":"Mock","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"31","key":"10.1016\/j.gore.2021.100878_b0095","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I\/II CheckMate 358 Trial","volume":"37","author":"Naumann","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.gore.2021.100878_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother."},{"issue":"1","key":"10.1016\/j.gore.2021.100878_b0105","first-page":"51","article-title":"Radiation treatment of primary carcinoma of the vagina. Patterns of failures after definitive therapy. Acta Radiol","volume":"24","author":"Prempree","year":"1985","journal-title":"Oncol."},{"issue":"1","key":"10.1016\/j.gore.2021.100878_b0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer."},{"issue":"3","key":"10.1016\/j.gore.2021.100878_b0115","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.ijrobp.2007.04.015","article-title":"Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum","volume":"69","author":"Samant","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"6","key":"10.1016\/j.gore.2021.100878_b0120","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00432-019-02915-1","article-title":"Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva","volume":"145","author":"Thangarajah","year":"2019","journal-title":"J Cancer Res Clin Oncol."},{"issue":"1","key":"10.1016\/j.gore.2021.100878_b0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0090-8258(86)90121-6","article-title":"Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study","volume":"23","author":"Thigpen","year":"1986","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.gore.2021.100878_b0130","doi-asserted-by":"crossref","unstructured":"Walle, T., et al. Radiation effects on antitumor immune responses: Current perspectives and challenges. Ther Adv Med Oncol 10: 1758834017742575, 2018. https:\/\/doi.org\/10.1177\/1758834017742575.","DOI":"10.1177\/1758834017742575"},{"key":"10.1016\/j.gore.2021.100878_b0135","unstructured":"Winer, I.S., Jones, N.L., Xiu, J., Ellerbrock, A., Brown, J., Herzog, T. Mutational burden, tumor PDL-1 expression, and microsatellite instability in gynecologic malignancies: Implications for immune Immune checkpoint expression, Poster 85 SGO 2018. https:\/\/www.sgo.org\/wp-content\/uploads\/2018\/03\/Abstracts-2018-SGO-Annual-Meeting-on-Womens-Cancer-1.pdf."},{"key":"10.1016\/j.gore.2021.100878_b0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/cxo.12200","article-title":"Wall-eyed bilateral internuclear ophthalmoplegia: review of pathogenesis, diagnosis, prognosis and management","volume":"98","author":"Wu","year":"2015","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.gore.2021.100878_b0145","unstructured":"www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm610572.htm (Accessed 10th Sept 2021)."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235257892100182X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235257892100182X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:55:48Z","timestamp":1762480548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235257892100182X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":29,"alternative-id":["S235257892100182X"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2021.100878","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2021.100878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100878"}}